[go: up one dir, main page]

CR5959A - Tratamiento para la disfuncion sexual femenina - Google Patents

Tratamiento para la disfuncion sexual femenina

Info

Publication number
CR5959A
CR5959A CR5959A CR5959A CR5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A CR 5959 A CR5959 A CR 5959A
Authority
CR
Costa Rica
Prior art keywords
apomorphine
treatment
sexual dysfunction
female sexual
clitoris
Prior art date
Application number
CR5959A
Other languages
English (en)
Inventor
El-Rashidy Ragab
Ronsen Bruce
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of CR5959A publication Critical patent/CR5959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LA DISFUNSION SEXUAL EN LA MUJER PUEDE SER AMINORADA, SIN EFECTOS SECUNDARIOS SUBSTANCIALES INDESEABLES POR LA ADMINISTRACION SUBLINGUAL DE DOSIS DE APOMORFINA. LA ADMINISTRACION DE APOMORFINA INCREMENTA LA ESTIMULACION DEL CLITORIS MEDIANTE EL FLUJO DE LA SANGRE INTRACAVERNOSAL Y EL FLUJO DE SANGRE EN LAS PAREDES DE LA VAGINA PARA OBTENER LA ERECCION DEL CLITORIS Y EL CONGESTIONAMIENTO VAGINAL DE LA MUJER. LA CONCENTRACION DE PLASMA DE APOMORFINA DE NO MAS DE 5.5 MANOGRAMOS POR MILILITRO ES PREFERIBLEMENTE MANTENIDA.
CR5959A 1998-01-30 1999-01-28 Tratamiento para la disfuncion sexual femenina CR5959A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
CR5959A true CR5959A (es) 1999-07-28

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
CR5959A CR5959A (es) 1998-01-30 1999-01-28 Tratamiento para la disfuncion sexual femenina

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
WO1999066909A2 (en) * 1998-06-22 1999-12-29 Univ Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20050070499A1 (en) * 1999-11-08 2005-03-31 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
CN1471395A (zh) 2000-04-07 2004-01-28 ����ҽҩƷ���޹�˾ 阿扑吗啡衍生物及其使用方法
DE60131644T2 (de) 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
EP1328281B1 (en) * 2000-06-27 2007-08-15 Qualilife Pharmaceuticals Inc. Compositions and methods for treating females sexual response
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (en) 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
WO2002039879A2 (en) 2000-11-15 2002-05-23 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
BR0110450A (pt) * 2000-11-22 2005-02-09 Abbott Lab Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
WO2002062315A1 (en) * 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
EP1496915A1 (en) * 2002-03-19 2005-01-19 Brain 'N' Beyond Biotech Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
WO2004089374A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
WO2006105615A1 (en) * 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US8349850B2 (en) * 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
CA2765291C (en) * 2009-06-12 2016-03-08 Adagio Pharmaceuticals Ltd. Sublingual apomorphine
WO2011130608A1 (en) * 2010-04-15 2011-10-20 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
KR101890317B1 (ko) * 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
EP3285771B1 (en) 2015-04-21 2025-02-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
WO1993023035A2 (en) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
PT758895E (pt) * 1994-04-22 2000-05-31 Univ Kingston Formas de dosagem sublingual contendo apomorfina para uso no tratamento da disfuncao erectil
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
GC0000096A (en) 2005-06-29
NZ506597A (en) 2003-07-25
EP1056419A4 (en) 2007-05-02
JO2085B1 (en) 2000-05-21
SK11362000A3 (sk) 2001-02-12
TR200002220T2 (tr) 2000-12-21
AR017976A1 (es) 2001-10-24
HUP0101268A2 (hu) 2001-09-28
CO4970819A1 (es) 2000-11-07
CN1250221C (zh) 2006-04-12
BG64667B1 (bg) 2005-11-30
KR20010040477A (ko) 2001-05-15
GT199900013A (es) 2001-07-20
AU752928B2 (en) 2002-10-03
JP2002501875A (ja) 2002-01-22
TW550069B (en) 2003-09-01
UY25374A1 (es) 1999-09-27
TNSN99008A1 (fr) 2005-11-10
BG104715A (bg) 2001-02-28
IL137569A (en) 2006-08-01
US6193992B1 (en) 2001-02-27
ZA99686B (en) 1999-07-28
HK1040901A1 (en) 2002-06-28
EP1056419A1 (en) 2000-12-06
PA8467801A1 (es) 2000-09-29
HK1040901B (zh) 2006-11-24
PL342062A1 (en) 2001-05-21
NO20003845L (no) 2000-09-28
HN1999000015A (es) 1999-08-23
WO1999038467A1 (en) 1999-08-05
CN1313742A (zh) 2001-09-19
NO20003845D0 (no) 2000-07-27
PE20000240A1 (es) 2000-03-31
BR9908038A (pt) 2002-01-02
IL137569A0 (en) 2001-07-24
US5945117A (en) 1999-08-31
PL194350B1 (pl) 2007-05-31
AU2564499A (en) 1999-08-16
HUP0101268A3 (en) 2002-12-28
NO319821B1 (no) 2005-09-19
MA26600A1 (fr) 2004-12-20
DZ2714A1 (fr) 2003-09-01
MXPA00007447A (es) 2006-01-25
CA2322289A1 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
CR5959A (es) Tratamiento para la disfuncion sexual femenina
EP1253929A4 (en) USE OF RELAXIN FOR THE TREATMENT OF DISEASES CONTAINED BY VASCARIAL CONSTRUCTION
EA200001044A2 (ru) Соединения для лечения женской сексуальной дисфункции
US5891915A (en) Method for enhancing female sexual response and an ointment therefor
EA199700213A1 (ru) Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений
ATE233091T1 (de) Verwendung von histamine-2 agonisten zur behandlung sexueller funktionsstörungen
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
RU2002104498A (ru) Применение тозилхлорамидов для лечения заболеваний кожи, слизистой оболочки, органов и тканей
US20080213407A1 (en) Topical application of L-arginine and menthol to increase penis size
AR019694A1 (es) Metodo para el tratamiento o reduccion de la disfuncion sexual femenina.
ES2042818T3 (es) Agente terapeutico para la trombocitopenia.
ECSP992843A (es) Procedimiento para aminorar la disfuncion sexual femenina
RU94031913A (ru) Способ лечения хронического кандидозного вульвовагинита
RU2224562C2 (ru) Способ лечения хронического простатита
RU2188675C2 (ru) Способ лечения больных с аменореей центрального генеза
TH65931A3 (th) ยาสำหรับหญิงที่เสื่อมสมรรถภาพทางเพศและวิธีการใช้
RU2529812C2 (ru) Биологически активная композиция
RU2048808C1 (ru) Средство, стимулирующее потенцию
محمد أكرم رنداوا et al. A Review of the Developmental, Structural, Biochemical, Pathophysiological and Pharmacological Similarities between Male and Female Genitals
MXPA02001219A (es) Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
RU95101168A (ru) Способ формирования желаемого пола зарождаемого ребенка
McCaffrey et al. THE HISTORY OF HYSTERIA AND THE EVOLUTION OF THE MANAGEMENT OF FEMALE SEXUAL DYSFUNCTION: 1098
TH51782A (th) การใช้ตัวยับยั้ง pde v
Hatzinger et al. CASTRATOS-EVERYTHING FOR FAME-: 1097

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)